Bernard Gordon R 4
4 · CUMBERLAND PHARMACEUTICALS INC · Filed Aug 30, 2019
Insider Transaction Report
Form 4
Bernard Gordon R
Senior Vice President
Transactions
- Sale
Common Stock
2019-08-27$5.11/sh−100$511→ 33,631 total - Sale
Common Stock
2019-08-26$5.16/sh−1,400$7,224→ 33,731 total - Sale
Common Stock
2019-08-30$5.11/sh−900$4,599→ 32,531 total - Sale
Common Stock
2019-08-28$5.02/sh−200$1,004→ 33,431 total - Sale
Common Stock
2019-08-23$5.33/sh−500$2,665→ 35,131 total
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies.
- [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.35 to $5.07, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.35 to $5.30, inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.16 to $5.15, inclusive.
- [F5]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.12 to $5.07, inclusive.